iRadimed Corporation (IRMD)
IRMD trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1325618/000110465926024691/0001104659-26-024691-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | IRMD on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001325618 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $83.8M |
| Net income | $22.5M |
| Operating income | $26.1M |
| Net margin | 26.8% |
| Operating margin | 31.2% |
| Revenue growth | +14.4% |
| Cash | $51.2M |
| Total assets | $108.8M |
| P/E (computed) | 48.3× |
| P/S (computed) | 12.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-30 |
| Cash and burn | $63.3M cash; operating cash flow $6.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 12,788,153 (2026-10-30); 12,721,156 a year earlier; 12,605,577 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | RSM US LLP, Orlando, Florida, United States | PCAOB Form AP 2026-03-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $20.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $24.2M | $6.5M | $7.0M | $63.3M | No debt tags | $89.3M | 10-Q 2026-10-30 |
| Q2 2026 2026-06-30 | $20.5M | $5.2M | $5.9M | $59.1M | No debt tags | $86.3M | 10-Q 2026-07-31 |
| Q1 2026 2026-03-31 | $22.0M | $5.8M | $8.3M | $56.4M | No debt tags | $86.3M | 10-Q 2026-05-01 |
| Q4 2025 2025-12-31 | $22.7M | $6.4M | $5.9M | $51.2M | No debt tags | $83.8M | 10-K 2026-03-06 |
| Q3 2025 2025-09-30 | $21.2M | $5.6M | $7.0M | $56.5M | No debt tags | $80.5M | 10-Q 2026-10-30 |
| Q2 2025 2025-06-30 | $20.4M | $5.8M | $7.7M | $53.0M | No debt tags | $77.6M | 10-Q 2026-07-31 |
| Q1 2025 2025-03-31 | $19.5M | $4.7M | $4.3M | $50.3M | No debt tags | $75.2M | 10-Q 2026-05-01 |
| Q4 2024 2024-12-31 | $19.4M | $5.1M | $6.0M | $52.2M | No debt tags | $73.2M | 10-K 2026-03-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2024-04-03 |
| Latest annual report | 10-K | 2026-03-06 |
| Latest quarterly / interim | 10-Q | 2026-10-30 |
| Latest current report | 8-K | 2026-10-30 |
| Latest proxy | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 777 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.1% |
| 1 month | -4.8% |
| 3 months | -2.1% |
| Year to date | -12.3% |
| 1 year | +1.0% |
| From 52-week high | -18.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IART | Integra LifeSciences Holdings Corporation | $13.98 | -2.92% | $1.1B |
| SGP | SpyGlass Pharma Inc. | $32.24 | -1.95% | $1.1B |
| DRTS | Alpha Tau Medical Ltd. | $11.97 | -10.54% | $1.1B |
| SIBN | SI-BONE Inc. | $23.41 | -0.13% | $1.1B |
| ATEC | Alphatec Holdings Inc. | $6.78 | -4.10% | $1.1B |
| TNDM | Tandem Diabetes Care Inc. | $18.48 | -7.92% | $1.3B |
| AORT | Artivion Inc. | $18.47 | -3.30% | $901.1M |
| NVCR | NovoCure Limited | $11.30 | -4.48% | $1.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier